Nature’s secret to longevity? It’s all about who you hang out with

(Photo by Joshua J. Cotten from Unsplash)

From meerkats to macaques, social animals tend to live longer, take more time to reach maturity, and have more extended reproductive periods than their more solitary counterparts, according to research from the University of Oxford.

Living in social groups comes with clear tradeoffs. On one hand, social animals can share resources, protect each other from predators, and help raise offspring together. On the other hand, they face increased risks of disease transmission, competition for resources, and social conflicts. Yet despite these challenges, scientists say the benefits of social living appear to outweigh the costs across the animal kingdom.

The study, published in Philosophical Transactions of the Royal Society B, examined 152 animal species across 13 taxonomic classes, from jellyfish to humans, providing the first broad evidence that sociality shapes animal life patterns across diverse species.

Previous research on the relationship between social behavior and animal demographics has typically focused on single species or specific groups like birds or mammals. This new study takes a wider view, examining how social behavior influences life patterns across the entire animal kingdom.

Rather than simply categorizing animals as either social or non-social, the researchers developed a novel spectrum of sociality with five distinct levels. At one end are solitary animals like tigers and cheetahs, which spend most of their time alone except for breeding. In the middle are “gregarious” animals like wildebeest and zebras that form loose groups, and “communal” species like purple martins that share nesting areas. “Colonial” species like some wasps and coral polyps always share living spaces. At the far end of the spectrum are highly social species like elephants, most primates, and honeybees, which form stable, organized groups with complex social structures and cooperative breeding.

This nuanced approach to classifying sociality helped reveal patterns that might otherwise have remained hidden. The study found that more social species not only tend to live longer but also have extended “reproductive windows” – the period during which they can successfully produce offspring. They’re also more likely to reproduce successfully before dying compared to less social species.

Consider the difference between social meerkats and solitary tigers. Meerkats live in cooperative groups where multiple individuals help raise young, take turns watching for predators, and maintain complex social hierarchies. Tigers, in contrast, are largely solitary except when mating or raising cubs. The research suggests that the meerkat’s social structure may contribute to their relatively long lifespan and extended reproductive period compared to similar-sized solitary animals.

However, the study also revealed some surprising findings about population resilience. While more social species showed greater resistance to environmental disturbances, they demonstrated lower ability to take advantage of favorable conditions compared to less social species. This suggests that while social living might provide individual advantages, it doesn’t necessarily help populations adapt quickly to environmental changes.

Interestingly, the research found no clear connection between sociality and senescence – the rate at which animals age or experience reproductive decline. Whether an animal lives in complex social groups or leads a solitary life doesn’t seem to affect how quickly it ages or loses reproductive capability over time.

The findings have particular relevance in our post-COVID era, where humans have experienced firsthand the impacts of social isolation.

“Sociality is a fundamental aspect of many animals. However, we still lack cross-taxonomic evidence of the fitness costs and benefits of being social. Here, by using an unprecedented number of animal species this work has demonstrated that species that are more social (most monkeys, humans, elephants, flamingos, and parrots) display longer life spans and reproductive windows than more solitary species (some fish, reptiles, and some insects),” says lead author Rob Salguero-Gómez, an associate professor with Oxford’s Department of Biology, in a statement.

“In a post-COVID era, where the impacts of isolation have been quite tangible to humans (a highly social species), the research demonstrates that, across a comparative lens, being more social is associated with some tangible benefits.”

 

Source: https://studyfinds.org/natures-secret-to-longevity/

Doctors struggle to treat long Covid patients in India; researchers point to inadequate studies

Inflammation persisting despite recovery from acute Covid infection is thought to lie at the heart of long Covid.

Here’s what to consider (Source: Getty Images/Thinkstock)

Doctors in India are grappling to diagnose and treat unexplained and persistent symptoms of long Covid patients due to limited guidelines, whereas researchers have flagged inadequate studies on the condition.

With the World Health Organization declaring an end to Covid as a global health emergency in May last year, focused efforts are underway around the world to estimate the burden of long Covid among the population.

The condition refers to the set of lingering symptoms affecting varied body parts and persisting well beyond the acute Covid infection period, including cough, muscle and joint pain, fatigue, brain fog and difficulty in focusing. The viral disease is caused by the SARS-CoV-2 virus.

While studies have suggested that about a third of those moderately or severely infected are likely to suffer from long Covid, region-wise though, incidence could vary.

A study by researchers, including those from Harvard Medical School, US, estimated that 31 per cent of the once-infected people in North America, 44 per cent in Europe, and 51 per cent in Asia, have long Covid, which is “challenging the healthcare system, but there are limited guidelines for its treatment”. It was published in the International Journal of Infectious Diseases in September.

One such study by Maulana Azad Medical College in New Delhi, conducted from May 2022 to March 2023 on 553 patients who had recovered from Covid, found that about 45 per cent had lingering symptoms, persistent fatigue and dry cough being the most common.

“There is limited exploratory research on the long Covid syndrome with scarce data on long-term outcomes,” the authors wrote in the study published in the journal Cureus in May this year.

Understanding the long-term effects of the virus is important for developing management strategies, optimising healthcare delivery, and providing support to recovered Covid patients in the community, they said.

Dr Rajesh Sagar, Professor of Psychiatry, All India Institute of Medical Sciences (AIIMS), New Delhi, said, “Looking at the current state of long Covid studies in India, it is too premature to say that we understand the condition well enough to know how to diagnose or treat it.”

Animesh Samanta, assistant professor at School of Natural Sciences in Shiv Nadar University, Greater Noida, said, “While studies in India highlight the growing recognition of neurological complications in long Covid patients, more focused research on neuroinflammation is needed.” Doctors, too, have reported a rise in patients complaining of symptoms that they did not have pre-Covid.

“People who never had asthma in the past, post-Covid, with every viral infection, they get a long cough, shortness of breath and wheezing, which require the use of inhalers or nebuliser,” senior consultant Dr Neetu Jain, who runs a post-Covid care clinic at Pushpawati Singhania Hospital and Research Institute, New Delhi, said.

Source: https://indianexpress.com/article/lifestyle/health/doctors-struggle-to-treat-long-covid-patients-india-researchers-point-inadequate-studies-9642347/

Is the XEC COVID variant different to the rest?

Some reports and social media users have raised concerns over the new COVID variant – but what are official health authorities saying?

File pic: iStock

The new COVID variant XEC has been found by UK health experts as they prepare for winter, when cases tend to increase.

The UK Health Security Agency (UKHSA) has highlighted a slight increase in hospitalisations amid COVID patients recently, with the admission rate at 4.5 per 100,000 people in the week to 6 October, up from 3.7 a week prior.

It is the fourth weekly rise in a row – and this, mixed with the UKHSA finding some XEC cases – has led to plenty of news coverage about the new variant.

It comes as a number of analysts on social media have tipped XEC to become the dominant strain and fuel a winter wave – but is it more of a threat than others?

The reality is that while the UKHSA is urging people to protect themselves from COVID generally, it has not “sounded the alarm” on XEC.

It has acknowledged that people may be concerned about new variants, adding around one in 10 of new cases it has analysed shows XEC lineage.

“Current information doesn’t suggest we should be more concerned about this variant but we are monitoring this closely,” says Dr Jamie Lopez Bernal, consultant epidemiologist at UKHSA.

What we know about XEC

XEC, like many other variants, is a part of the Omicron family.

It was first found in May, according to the World Health Organization (WHO), which says it is a so-called recombinant of two other strains – KS.1.1 and KP.3.3 – meaning that genetic information was exchanged between them to form a third strain, XEC.

In its last COVID update on 9 October, the WHO said XEC was one of only two variants that was showing “increasing prevalence globally” between 19 August and 15 September – but it was still only responsible for a small percentage of cases, with KP.3.3 responsible for almost half of the cases worldwide.

In the UK, XEC was identified in 9.35% of COVID cases in samples taken by the UKHSA between 2 September 2024 and 15 September 2024, while 59.35% were identified as KP.3.3.

What are the symptoms of XEC?

No health organisations have listed any symptoms specific to XEC.

It is said to have the same symptoms as other COVID variants, including:

• a high temperature
• a new, continuous cough
• a loss or change to your sense of smell or taste
• shortness of breath
• feeling tired or exhausted
• an aching body
• a headache
• a sore throat
• a blocked or runny nose.

 

Source: https://news.sky.com/story/xec-covid-variant-how-dangerous-is-it-13234045

Ex-Fauci top adviser offers apologies and excuses after COVID email revelations

ICMR calls out BHU study on Covaxin side effects, says poorly designed: Find out why

It ‘incorrectly and misleadingly’ acknowledges ICMR, which did not offer any financial or technical support for the paper

Covaxin research icmrA health worker prepares a Covaxin dose during a vaccination drive in Kolkata on January 4, 2022. (Express photo by Partha Paul)

Days after a Banaras Hindu University (BHU) study reported long-term adverse events of “special interest” in a group of over 900 people a year after they were vaccinated with Bharat Biotech’s Covaxin, the Indian Council of Medical Research (ICMR) has called it a “poorly designed study” with critical flaws.

The director-general of the apex medical research body has also written to the authors of the paper and the editor of the journal in which it was published, stating that it “incorrectly and misleadingly” acknowledges ICMR though the body did not offer any financial or technical support for the paper. “ICMR cannot be associated with this poorly designed study,” say the letters.

Why did ICMR denounce the paper?

According to ICMR, the study has four critical flaws. One, it does not have a control group of unvaccinated individuals to prove that the side-effects are indeed associated with vaccination. Two, it does not mention how frequently these adverse events were reported by the sample population to establish that they were associated with vaccination. Three, the study tool was not consistent with the definition of “adverse events of special interest” that is globally accepted. Four, the responses of the participants were recorded one year after immunisation without verification of any clinical records or physician examination, increasing the chances of biased reporting.

According to the methodology mentioned in the paper, the researchers contacted over 1,000 adolescent and adult recipients of the vaccine telephonically 14 days after immunisation to check whether they had experienced any side effects. The researchers again contacted the recipients one year later — when 926 of the 1,024 initial participants answered — to check whether any of the symptoms persisted or whether they had developed any other side effects of “special interest.”

What did the research claim?

The study claimed that over a one-year follow-up, over 40 per cent of the participants reported upper respiratory tract infections that were not confirmed to be Covid-19. It said 10.5 per cent adolescents developed new skin or under-skin disorders and 4.7 per cent developed nervous system disorders. Among adults, the study said, 5.8 per cent reported musculoskeletal disorders and 5.5 per cent nervous system disorders. About 4.6 per cent of girls and women reported menstrual abnormalities. And 0.3 per cent of the participants experienced strokes and 0.1 per cent had Guillain Barre syndrome — a rare disorder where the immune system starts attacking the nerves.

Source: https://indianexpress.com/article/health-wellness/covaxin-side-effects-bhu-study-icmr-9340377/

What Is FLiRT, New Covid Variant? 5 Pointer Round-Up About Latest Strain

The latest Covid strain, FLiRT, is causing rise in viral cases in US. Here is a total round-up about the latest variant.

What is FLiRT, New Covid Variant? 5 Pointer Round-Up About Latest Strain (Freepik)

Anxiety buttons have been triggered as the news of a new Covid strain is making the headlines again. FLiRT is a new set of Covid variants, from the lineage of the highly transmissible and immune system evading Omicron. The FLiRT variants, which majorly include KP.1.1, and KP.2, are named based on the technical names for their mutations, one of which includes the letters “F” and “L”, and another of which includes the letters “R” and “T”. According to data from the US Centers for Disease Control and Prevention, KP.2 accounted for about one in four or 25 per cent of new sequenced cases in the country in the last weeks of April.

FLiRT NEW COVID VARIANT: ALL YOU NEED TO KNOW

  1. Symptoms of new covid strain are: sore throat, runny nose, congestion, tiredness, fever (with or without chills), headache, muscle pain, and sometimes loss of taste or smell.
  2. While the variants are likely to be “more transmissible and defy immunity as compared to previous strains”, they are unlikely to produce severe symptoms in the form of pneumonia”, Dr Dhiren Gupta, Senior Consultant, Dept of Paediatric Pulmonology and Allergy, Sir Ganga Ram Hospital, told IANS.
  3. The new Covid-19 variant ‘FLiRT’, which is spreading fast in the US, is capable of evading the immune system due to a trans substitution of amino acids between two spike proteins, the experts said on Sunday.
  4. FLiRT, which belongs to Omicron’s JN.1 lineage, is rapidly replacing the previous variant, Eris, in the US
  5. So, far, experts have asked not to create a wave of panic. Doctors highlight how crucial are lifestyle habits  and how it should be focussed on to prevent contraction of virus. FLiRT has certain concerning features, like change in spike protein, that still need more research to determine its severity.

“Only patients who are having severe uncontrolled comorbidities or chronic lung diseases should be a little precautious about getting infected as it can worsen their existing symptoms,” he added. The mortality rate has not been increased so far.

AstraZeneca admits its vaccine causes clotting: Why Covishield vaccine takers in India shouldn’t panic

Experts explain post-vaccination risks and do the risk-benefit analysis

A 2022 study in Lancet Global Health found that AstraZeneca had reported rates of 8.1 TTS cases per million receiving the first dose and 2.3 TTS cases per million receiving the second dose.A 2022 study in Lancet Global Health found that AstraZeneca had reported rates of 8.1 TTS cases per million receiving the first dose and 2.3 TTS cases per million receiving the second dose. (Express File Photo)

Global pharmaceutical manufacturer AstraZeneca has admitted that its Covid-19 vaccine, developed by researchers from the Oxford University, can cause a rare side effect of blood clotting and low platelet count after immunisation. In India, the same vaccine, called Covishield and manufactured by the Pune-based Serum Institute, has been administered through 175 crore doses. Understandably, this raises questions as to the safety of the jab all of us took.

The company made this admission of a side effect, Thrombosis with Thrombocytopenia Syndrome (TTS), in court as it faces a lawsuit alleging severe harm and deaths caused by the vaccine, according to The Daily Telegraph. While this may be the company’s first admission in court, TTS has been well-documented and accepted in scientific literature. The first cases came to light within months of the vaccination drives beginning in Europe, with some countries halting the use of the AstraZeneca vaccine for a while.

WHAT DOES THE CASE MEAN FOR COVISHIELD USERS IN INDIA?

The Government committee on Adverse Events Following Immunisation (AEFI), vetted at least 36 cases of TTS and confirmed 18 deaths from it in 2021, the first year of Covid-19 vaccination in the country. However, it is unlikely that affected Indian patients can join the British petition due to legal hurdles such as approvals coming from different regulators and the product being manufactured by an Indian company, which is subject to Indian jurisdiction and laws.

WHY IS THERE NO NEED TO PANIC?

Experts say that TTS was reported early on in the pandemic by European countries but it was very rare in India. A senior health ministry official, who was part of the discussions on the vaccination drive says, “TTS is a very rare side effect, rarer still in Indians and South Asians as compared to Europeans. But there is enough evidence to show that vaccination saved lives — the benefits outweighed the risks.”

Besides, the risk is not only rare but is high only in the first few weeks after the first vaccination. Most Indians have already had three shots and it has been a long time since. Says Dr Gagandeep Kang, Director of Global Health at the Bill and Melinda Gates Foundation, who was on the WHO safety advisory committee for COVID-19 vaccines, “It is most important to reassure people that the risk of TTS is shortly after vaccination. We are all long past vaccination now,” she adds.

“It is surprising that people are reacting now. The rare side effect was well documented and scientifically accepted even when the vaccination drives were going on. The benefit of vaccination at the height of the pandemic outweighed the risk,” says Dr Anurag Agarwal, Dean of Biosciences and Health Research at the Trivedi School of Biosciences of Ashoka University.

Besides, the package insert for Covishield always came with a warning about the rare condition. “A very rare and serious (side effect) … has been observed following vaccination with ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) during post-authorisation use… Cases have occurred in patients with a previous history of thrombosis, as well as in patients with autoimmune disorders. The benefits and risks of vaccination should be considered in these patients.”

A 2022 study in Lancet Global Health found that AstraZeneca had reported rates of 8.1 TTS cases per million receiving the first dose and 2.3 TTS cases per million receiving the second dose. The study also showed that there was a geographic variation in the reporting of TTS, with the highest cases coming from Nordic countries (17.6 per million doses) and the lowest from Asian countries (0.2 per million doses).

Besides, the package insert for Covishield always came with a warning about the rare condition. “A very rare and serious (side effect) … has been observed following vaccination with ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) during post-authorisation use… Cases have occurred in patients with a previous history of thrombosis, as well as in patients with autoimmune disorders. The benefits and risks of vaccination should be considered in these patients.”

A 2022 study in Lancet Global Health found that AstraZeneca had reported rates of 8.1 TTS cases per million receiving the first dose and 2.3 TTS cases per million receiving the second dose. The study also showed that there was a geographic variation in the reporting of TTS, with the highest cases coming from Nordic countries (17.6 per million doses) and the lowest from Asian countries (0.2 per million doses).

Source: https://indianexpress.com/article/health-wellness/astrazeneca-vaccine-clotting-covishield-vaccine-india-9299683/

COVID’s Alarming Potential To Trigger Rare Paralysis Disorder Revealed

(© sergign – stock.adobe.com)

Researchers have found a concerning association between COVID-19 infection and an increased risk of developing the rare disorder Guillain-Barré syndrome over the following six weeks. However, the study authors, working with the American Academy of Neurology, also note those who received the Pfizer-BioNTech mRNA vaccine showed a lower risk of developing Guillain-Barré syndrome in comparison to others who did not receive the vaccine.

Guillain-Barré syndrome is a rare autoimmune disorder that causes the immune system to attack nerve cells and portions of the peripheral nervous system. Symptoms usually begin with weakness in the hands and feet before eventually progressing to full-blown paralysis. While it can be life-threatening if left untreated, the majority of Guillain-Barré patients make a full recovery.

The exact cause of Guillain-Barr syndrome remains a mystery, but it often develops after gastrointestinal or respiratory infections. Researchers note the rare disorder develops in up to 20 out of every one million people annually, and cases following certain vaccinations are extremely rare.

“These findings further highlight the benefits of ongoing vaccination programs with mRNA-based vaccines,” says study author Anat Arbel, MD, of Lady Davis Carmel Medical Center in Haifa, Israel. “The results have important clinical and public health implications,” in a media release.

Those who received the Pfizer-BioNTech mRNA vaccine showed a lower risk of developing Guillain-Barré syndrome (Photo by CDC on Unsplash)

This project assessed over three million people living in Israel, all of whom had no previous history of Guillain-Barr. Researchers tracked participants starting from Jan. 1, 2021 until June 30, 2022. During that period, 76 individuals developed Guillain-Barr. The study authors then matched each Guillain-Barr patient to 10 people who did not have the syndrome (760 people in total).

Next, the research team assessed whether participants had a COVID infection or a COVID vaccine over the six weeks prior to being diagnosed with Guillain-Barré (or the same period among matched participants).

This approach led to the finding that those with a recent COVID infection were six times more likely to develop Guillain-Barré than others who had gone without an infection. In all, 12 percent of those with Guillain-Barré had a recent COVID infection, in comparison to just two percent of the people who did not have Guillain-Barré.

Additionally, 11 percent of Guillain-Barré patients had been recently vaccinated with an mRNA vaccine, in comparison to 18 percent of those who did not have Guillain-Barré. All in all, the study estimates people with a recent mRNA vaccination were over 50 percent less likely to develop Guillain-Barré than the unvaccinated.

Source: https://studyfinds.org/covid-19-guillain-barre/

CDC issues health alert for bird flu infection in US

A person touches a test tube labelled “Bird Flu”, in this picture illustration, January 14, 2023. REUTERS/Dado Ruvic/Illustration/File Photo Purchase Licensing Rights

The U.S. CDC on Friday issued a health alert to inform clinicians, state health departments and the public of a case of avian influenza in a person who had contact with dairy cows presumed to be infected with the virus.
The farm worker from Texas was reported to be infected on April 1, making it the second case of the H5N1 strain of avian influenza, commonly known as bird flu, identified in a person in the United States.
It follows a 2022 case in Colorado, and comes as the virus is spreading to new mammals, including dairy cattle for the first time.
To prevent infection from the virus, the CDC recommends the use of personal protective equipment (PPE), testing, antiviral treatment, patient investigations and monitoring of persons exposed to sick or dead, wild and domesticated animals and livestock that may have been infected with the virus.
Earlier this week, the CDC said the infection does not change the risk assessment for the U.S. general public from H5N1 bird flu, which it considers to be low. The Texas patient’s only symptom was eye inflammation, according to the state’s health department.

Measles outbreak warning: WHO sounds alarm as cases rise in Florida after Covid pandemic

Measles cases are rising in Florida (Image: Getty)

More than half the world’s countries will be at a “high or very high” risk of measles by the end of 2024 unless urgent action is taken by governments to protect children, the World Health Organization (WHO) warned.

Measles has been on the rise across most regions, especially due to a high amount of missed vaccinations during the COVID-19 pandemic when health systems were overrun with an excessive amount of patients.

Natasha Crowcroft, senior technical adviser on measles and rubella for WHO, said in a press conference in Geneva: “What we are worried about is this year, 2024, we’ve got these big gaps in our immunization programs, and if we don’t fill them really quickly with the vaccine, measles will just jump into that gap.

“We can see, from data that’s produced with WHO data by the CDC, that more than half of all the countries in the world are going to be at high or very high risk of outbreaks by the end of this year.”

Evidence of rising cases is clear in the US, where Florida recorded its seventh case of the virus on Friday – a child under the age of five. The child is the youngest to be infected in the outbreak and lives in Brownard County, officials said.

Measles, according to the WHO, is a “highly contagious, serious airborne disease caused by a virus that can lead to severe complications and death.”

The disease is common in children, but can seriously affect all age groups, according to the Centers for Disease Control and Prevention (CDC).

Measles can be extremely dangerous to a certain group of people, including children younger than five years, adults older than 20 years, pregnant women, and people with weakened immune systems from other diseases like leukemia and HIV infection.

Symptoms include high fever, cough, runny nose, and red, watery eyes in the first seven to 14 days after exposure.

Though measles vaccines were introduced in 1963, an estimation of 128,000 people died from measles in 2021, especially children under the age of five, the WHO reported.

According to the WHO, the COVID-19 pandemic exacerbated a setback in providing immunization services, leaving millions of unvaccinated children vulnerable to measles and increasing the likelihood of spreading to communities.

Crowcroft cited data saying that more than 306,000 measles cases were reported globally last year, marking a 79 percent increase from 2022.

She added that deaths increased by 43 percent in 2022, exceeding 130,000 deaths due to the disease.

This year, a total of 35 measles cases so far have been reported by 15 jurisdictions across the United States, according to data from the Centers for Disease Control and Prevention (CDC).

The states include Arizona, California, Florida, Georgia, Indiana, Louisiana, Maryland, Minnesota, Missouri, New Jersey, New York City, Ohio, Pennsylvania, Virginia, and Washington.

The CDC noted the measles cases in these states are often associated with an increase in the number of people who travel abroad, as well as spreading it with communities of unvaccinated people.

Source: https://www.the-express.com/news/health/129023/measles-outbreak-warning-who-pandemic-covid

Asia, Europe see spike and a WHO warning: Global Covid-19 surge weekly round-up

Covid-19 surge: Delta and Omicron variants continue to dominate a fresh wave in Asia with China, Hong Kong, Singapore and South Korea witnessing a surge daily cases. Here’s a round-up of the Covid-19 surge across the world in 10 points
A worker wearing protective gear looks on as people wait to be tested for the Covid-19 coronavirus at a residential compound in Shanghai.(AFP)

The pandemic was a long way off, the World Health Organization warned this week, with several nations across the world witnessing a spike in Covid cases yet again. With some South East Asian nations also seeing a surge, India has been prompted to keep the guards up. China is battling with a rise in daily cases driven by the highly infectious ‘stealth Omicron variant’. The country saw its first deaths since January 2021 this week.

Here’s a round-up of the Covid surge across the world in 10 points:

1. Delta and Omicron variants continue to dominate a fresh wave in Asia with China, Hong Kong, Singapore and South Korea witnessing a surge in coronavirus infections.

2. China’s national health authorities reported two Covid-19 deaths, the first recorded rise in death toll since January 2021, as the country battles a surge, reports said. China reported only two Covid deaths for all of 2021, the last of those on Jan 25.

3. Singapore on Saturday reported 10,244 new cases, taking the total tally to 1,007,158, according to news agency ANI. Three deaths were also reported on Saturday, bringing the overall count to 1,194.

Source: https://www.hindustantimes.com/world-news/global-covid-19-surge-weekly-round-up-asia-europe-see-spike-and-a-who-warning-101647743406688.html?utm_source=whatsapp&utm_medium=social&utm_campaign=ht_site

Covid Peak in S. Korea, Lockdown in China, New Variant in Israel: WHO Warns of New Wave

Workers wearing protective gear are pictured outside a closed off and locked down area after the detection of new cases of Covid-19 in the Huangpu district of Shanghai. (AFP)

After many weeks of downfall, the Covid graph is plateauing again across countries including China, Korea and Hong Kong. While 30 million people are forced under lockdown in China and morgues running out of space in Hong Kong, the pandemic doesn’t appear to be heading towards its end.

Israel has recorded two cases of a new variant, which is a combination of two sub-variants of the Omicron version of the Covid-19. A new wave of infections from the Omicron is moving towards the east of Europe as cases have more than doubled in Armenia, Azerbaijan, Belarus, Georgia, Russia and Ukraine, according to WHO.

Amid the new surge and concern over the new strain, News18 looks at the surge, the WHO’s response and whether a second booster would curb the new wave:

Omicron Peak in South Korea

South Korea reported a record of more than 600,000 coronavirus cases Thursday, with authorities saying the country was near the peak of an Omicron-fuelled infection wave.

According to WHO data, South Korea leads the world in newly reported cases in the last seven days with 2,417,174 infections, followed by Vietnam with 1,776,045.

Source : https://www.news18.com/news/world/covid-peak-in-s-korea-lockdown-in-china-new-variant-in-israel-who-issues-warning-on-new-wave-4884077.html

Centre Rings Alarm Amid Covid Comeback in China, Calls for Genome Sequencing, Surveillance At High-Level Meet

Union Health Minister Mansukh Mandaviya on Wednesday chaired a high-level meeting in the wake of a humongous rise in the Covid-19 cases in China and South East Asia. Official sources told News18 that Mandaviya asked for a high level of alertness, aggressive genome sequencing and intensified surveillance. The meeting was attended by top health officials, including the health secretary, pharma secretary and the principal scientific adviser to the Government of India, sources added.

People queue up to be tested as a measure against the Covid-19 next to a compound in Hongkou district, in Shanghai on March 16, 2022. (AFP)

The meeting comes as China is seeing a comeback of Covid-19 cases led by an Omicron-led outbreak with the country on Wednesday reporting 3,290 fresh infections. China also huddled to free up hospital beds as the highly transmissible Omicron variant is posing a stern challenge to its zero-Covid strategy, resulting in the 17.5 million residents of the southern tech hub of Shenzhen being locked down and other cities also under tight restrictions.

Meanwhile, mortuaries in Hong Kong are overflowing with Covid victims as the country is reeling under a deadly outbreak led by the Omicron variant.

Source: https://www.news18.com/news/india/centre-rings-alarm-amid-covid-comeback-in-china-calls-for-genome-sequencing-surveillance-at-high-level-meet-4881719.html

A covid surge in Western Europe has U.S. bracing for another wave

A surge in coronavirus infections in Western Europe has experts and health authorities on alert for another wave of the pandemic in the United States, even as most of the country has done away with restrictions after a sharp decline in cases.

Infectious-disease experts are closely watching the subvariant of omicron known as BA.2, which appears to be more transmissible than the original strain, BA.1, and is fueling the outbreak overseas.

What to know about BA.2, a new version of the omicron variant

Germany, a nation of 83 million people, saw more than 250,000 new cases and 249 deaths Friday, when Health Minister Karl Lauterbach called the nation’s situation “critical.” The country is allowing most coronavirus restrictions to end Sunday, despite the increase. Britain had a seven-day average of 65,894 cases and 79 deaths as of Sunday, according to the Johns Hopkins University Coronavirus Research Center. The Netherlands, home to fewer than 18 million people, was averaging more than 60,000 cases the same day.

In all, about a dozen nations are seeing spikes in coronavirus infections caused by BA.2, a cousin of the BA.1 form of the virus that tore through the United States over the past three months.

In the past two years, a widespread outbreak like the one now being seen in Europe has been followed by a similar surge in the United States some weeks later. Many, but not all, experts interviewed for this story predicted that is likely to happen. China and Hong Kong, on the other hand, are experiencing rapid and severe outbreaks, but the strict “zero covid” policies they have enforced make them less similar to the United States than Western Europe.

Source: https://www.msn.com/en-us/news/us/a-covid-surge-in-western-europe-has-us-bracing-for-another-wave/ar-AAV8kgb?ocid=sw

China’s soaring COVID infections fuel concern about cost of containment

 China posted a steep jump in daily COVID-19 infections on Tuesday, with new cases more than doubling from a day earlier to hit a two-year high, raising concerns about the rising economic costs of its tough measures to contain the disease.

Residents wearing face masks line up at a makeshift nucleic acid testing site during a mass testing for the coronavirus disease (COVID-19), in Chaoyang district of Beijing, China March 14, 2022. REUTERS/Tingshu Wang

A total of 3,507 domestically transmitted cases with confirmed symptoms were reported on Monday across more than a dozen provinces and municipalities, up from 1,337 a day earlier, the National Health Commission said.

Most of the new cases were in the northeastern province of Jilin.

Though China’s caseload is still tiny by global standards, health experts said the increase in daily infections over the next few weeks would be key to determine whether its “dynamic zero-COVID” approach, of containing each outbreak quickly as it arises, remains effective against the rapidly spreading Omicron variant.

Makers of everything from flash drives to glass for Apple’s iPhone screens are warning of shipment delays as they comply with China’s curbs against the disease, putting further strain on global supply chains.

A COVID-19 forecasting system run by Lanzhou University in China’s northwest predicted the current round of infections will eventually be brought under control in early April after an accumulated total of about 35,000 cases.

Source: https://www.reuters.com/world/china/china-reports-3602-new-confirmed-coronavirus-cases-march-14-vs-1437-day-earlier-2022-03-15/

China reports sharp rise in COVID-19 cases

The northeastern province of Jilin was worst hit, accounting for more than 3,000 cases, according to the National Health Commission.

China reported 5,280 new Covid-19 cases on Tuesday, more than double the previous day’s tally and the highest daily count since the start of the pandemic.

The northeastern province of Jilin was worst hit, accounting for more than 3,000 cases, according to the National Health Commission.

Since the coronavirus first emerged in the central city of Wuhan in late 2019, China had successfully suppressed large-scale outbreaks through its strict “zero-Covid” strategy, which involved hard lockdowns that confined huge sections of the population to their homes.

But Tuesday was the sixth day in a row that more than 1,000 new cases were recorded in the world’s second-biggest economy.

At least 11 cities and counties nationwide have been locked down because of the latest surge, including the southern tech hub of Shenzhen, home to 17 million people.

Source: https://www.moneycontrol.com/news/world/china-reports-sharp-rise-in-covid-19-cases-8232991.html

COVID-19 vaccine for 12-14-year-olds to start from March 16; all above 60 years can take boosters

The new decision will mean that, while Corbevax will be offered to the younger adolescents, those in the 15-17-year age group will continue to get Covaxin.

More than two months after opening COVID-19 vaccination for the 15-17-year age group in the country, the Centre has now announced plans to expand the programme further to include the 12-14-year age group, beginning March 16. The estimated population of this age group in India is 7.11 crore, said government sources.

The younger adolescents will be offered Corbevax by Hyderabad based Biological E, a receptor binding domain protein sub unit vaccine, developed in collaboration with the USA’s Baylor College.

This vaccine, to be administered in two doses given 28 days apart, was granted the emergency use authorization by the Drug Controller General of India for use in 12-plus population groups in December last year.

The health ministry said that the decision has been taken following “due deliberations with scientific bodies”.

This means that those born in 2008-2010 will now also be eligible for shots against COVID-19.

Importantly, the government has also decided that the condition of co-morbidity for COVID-19 precaution dose for population over 60 years of age will now be removed from March 16.

In other words, the entire population above 60 years of age will be eligible for COVID-19 booster doses.

Only Covaxin, the COVID-19 vaccine by Bharat Biotech, is permitted for the 15-17-year age group, whose population is estimated at 7.4 crore.

Beginning January 10, 2022, healthcare and frontline workers apart from those above 60 years with underlying diseases were eligible for precaution doses, provided that they had completed 9 months since their second dose.

Who needs to get tested for COVID-19? ICMR issues advisory on ‘purposive testing strategy’

New Delhi: As India’s COVID-19 cases continue to rise, the Indian Council of Medical Research has released an advisory on “Purposive Testing Strategy”, suggesting that some individuals need not be tested for infection. The guidelines come even as India’s daily COVID-19 tally hovered near the 1.8 lakh mark on Monday morning. The ICMR document makes no mention of contact tracing norms.

According to the newly released advisory, asymptomatic individuals, patients being discharged from a COVID-19 facility as per revised discharge policy as well as those discharged in line with home isolation guidelines need not be tested. Contacts of confirmed cases of COVID-19 need not be tested unless identified as high risk based on age or comorbidities, the ICMR said.

Symptomatic patients and at-risk contacts of COVID-19 patients (senior citizens and comorbid individuals) will need to get tested.

While individuals undertaking inter-state domestic travel do not need to be tested, the ICMR has said that international travellers will need to get tested. International travellers arriving at Indian airports and ports of entry as per laid down guidelines must also get tested.

New Source : https://www.timesnownews.com/india/article/who-needs-to-get-tested-for-covid-19-icmr-issues-advisory-on-purposive-testing-strategy/848147

 

Exit mobile version